Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PROREPAIR-B
- 04 Jun 2019 Results assessing pattern of disease progression (PSA, radiographic, clinical) in docetaxel versus Abiraterone + enzalutamide treated patients presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 16 Feb 2019 Results analysing association of time to PSA progression and radiographic progression-free survival with overall survival, presented at the 2019 Genitourinary Cancers Symposium.
- 01 Feb 2019 Status changed from active, no longer recruiting to completed.